Recombinant human erythropoietin therapy in critically ill Jehovah's Witnesses.

Department of Pharmacy, the Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.
Pharmacotherapy (Impact Factor: 2.2). 12/2008; 28(11):1383-90. DOI: 10.1592/phco.28.11.1383
Source: PubMed

ABSTRACT Blood transfusions and blood products are often given as a life-saving measure in patients with critical illness. However, some patients, such as Jehovah's Witnesses, may refuse their administration due to religious beliefs. Jehovah's Witnesses accept most available medical treatments, but not blood transfusions or blood products due to their religion's interpretation of several passages from the Bible. Since recombinant human erythropoietin (rHuEPO) became available, several cases have been reported in which rHuEPO was successfully administered to critically ill Jehovah's Witnesses. Administration of rHuEPO in combination with other blood conservation techniques has been shown to increase hemoglobin levels and survival in patients who experienced trauma, burns, general surgery, or gastrointestinal hemorrhage. We performed a literature search of the MEDLINE and International Pharmaceutical Abstracts databases of rHuEPO therapy in the Jehovah's Witness population. Fourteen cases were identified in which rHuEPO was administered to Jehovah's Witnesses who required the drug for critical care resuscitation as an alternative to blood products. In each clinical situation, rHuEPO enhanced erythropoiesis; however, time to the start of treatment, dosages, route of administration, and treatment duration varied widely. Supplementation with adjunctive agents, such as iron, folic acid, and vitamin B12, was also beneficial. Use of rHuEPO in Jehovah's Witnesses may provide an alternative to blood transfusions or blood products. Other alternatives, such as hemoglobin-based oxygen carriers and perfluorocarbons, are also being explored.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background:Erythropoiesis stimulating agents [erythropoietin (EPO)] have been recommended to treat anaemic patients who cannot receive or refuse blood tranfusion (‘untransfusable’ patients).Objective:The objective of the study was to quantify the association of EPO use with haemoglobin (Hgb) recovery in anaemic untransfusable hospitalised patients.Methods/materials:EPO treated anaemic untransfusable patients were identified through the combination of a retrospective case review and a systematic review of the medical literature. Literature reports of untransfusable patients not treated with any EPO were used as a comparator group. Hgb concentrations before and following EPO use were abstracted and used to determine the rate of Hgb recovery for each case. Multilevel mixed effects modelling was used to determine the association of Hgb recovery with EPO use.Results:A total of 76 EPO treated cases (19 cases from the retrospective hospital case review and 57 from the literature), and 33 non-EPO treated comparator patients from the literature were included in the study. Hgb increased similarly over time in all groups at an overall mean standard error (SE) rate of 0·13 (0·01) g dL−1 day−1. The Hgb recovery rate was higher in patients with lower baseline Hgb, regardless of EPO use. No association was found between the rate of Hgb recovery and EPO use, dose or therapy duration.Conclusions:In anaemic, ‘untransfusable’ hospitalised patients, EPO use was not associated with increased Hgb recovery at anytime within 28 days.
    Transfusion Medicine 04/2014; 24(4). DOI:10.1111/tme.12120 · 1.31 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The objective of this study was to understand the determinative factors for packed red cell transfusions in elective digestive tract surgeries in four hospital units in Montes Claros, Minas Gerais, Brazil. Retrospective analyses were performed by collecting data from the clinical records of patients submitted to elective digestive tract surgeries from June 2007 to December 2008 at these four hospital units. Eighty-one cases (42% females and 58% males) were included in this study. The average age was 55.5 years old (Standard deviation ± 19.11 years). The commonest reported underlying disease was neoplasia (42%). Of these patients, 38 (47%) were transfused in the immediate preoperative period, 28 (34.6%) during the surgery and 37 (45.7%) in the immediate postoperative period. In the univariate analysis, there was an association between the data of transfusions and the different institutions. In the surgical phase, there were correlations between transfusion and the reason for transfusion, RH factor (Rhesus), institutional policy and the underlying disease. In the postoperative phase, no association was identified. In all phases, there were not correlations between the type of surgical procedures, ASA index (American Society of Anesthesiology), and hemoglobin and hematocrit values. Therefore, this study demonstrated that the blood transfusions in elective digestive tract surgeries were heterogeneous between hospitals and were not related to specific laboratorial values; they were associated to the underlying pathology, but not with the type of surgical procedure and generally followed the criteria of the healthcare specialist.
    Revista Brasileira de Hematologia e Hemoterapia 12/2009; 32(5):371-377. DOI:10.1590/S1516-84842010000500009
  • [Show abstract] [Hide abstract]
    ABSTRACT: The Institute for Patient Blood Management and Bloodless Medicine at the Englewood Hospital has considerable experience in managing patients with gastrointestinal bleeding who do not accept blood-derived products. We present our data and experience over the last 8 years in managing such patients.
    Journal of Clinical Gastroenterology 08/2014; DOI:10.1097/MCG.0000000000000200 · 3.19 Impact Factor